Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-787 in Severe Alcohol-Associated Hepatitis (Phase 2a)
2022-001639-10Phase 2Active
- Sponsor
- Intercept Pharmaceuticals
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol-associated hepatitis (AH) and alcoholic hepatitis (AH) comparing INT-787 with Placebo (2 arms). Primary endpoint: Markers of Efficacy (Primary). Started Dec 2022; status: active.
02
Drugs
INT-787
03
Conditions
alcohol-associated hepatitis (AH)alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2022-001639-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001639-10.